According to "The Hindu" article, around 70% of all hospital admissions were in the private sector and around 90% of critical patients were admitted in private hospitals in pre-pandemic times. But with COVID cases, that scenario was reversed and over 70% of COVID patients were recovering at government facilities. With improving healthcare facilities and the complexity of the health care system, patients have many choices while receiving care. Improving healthcare facilities will directly affect the efficiency and advancement of diagnostics. With the advent of technologies and rise in healthcare expenditure toward improving the healthcare system, epigenetics diagnostic flourished while providing accuracy and early diagnosis, preventing the rise in chronic disease prevalence. Hence, improving healthcare facilities, specifically infrastructure and patient care, is expected to escalate the growth of the market.
Access Full Report @ https://www.databridgemarketresearch.com/jp/reports/global-epigenetics-diagnostic-market
Data Bridge Market Research analyses that the epigenetics diagnostic market is expected to grow at a CAGR of 15.2% in the forecast period of 2021 to 2028 and is expected to reach USD 12,505.91 million by 2028. Growing R&D) activities allow companies to stay forward in the epigenetics diagnostic market competition. Epigenetic changes allow cells to control and regulate gene activity without permanently changing the genes. Whereas epigenetic control relies on small, reversible, changes to the DNA and proteins that make up chromosomes. Moreover, research and development activities offer tremendous benefits to the company and provide various diagnostics to provide early diagnosis and appropriate treatment of target diseases. Thus, rise in R&D activities and increase in public and private funding for cancer research is expected to propel the growth of market.
Rising Prevalence of Cancer globally is expected to drive the market's growth rate
The rapid increase in cancer prevalence has made it the second leading cause of death after cardiovascular disease worldwide. Factors such as tobacco smoking, urbanization, pollution, and sedentary lifestyle are considered responsible for this phenomenon. In addition, epigenetic events such as DNA methylation are equally accountable for cancer initiation and progression as genetic abnormalities. Epigenetic events are essential in normal biological processes as well as in tumorigenesis and alterations in epigenetic modifications during cancer initiation, regulating various cellular responses, including cell proliferation, apoptosis, invasion, and senescence. This makes epigenome-targeted therapy a promising strategy for the treatment of cancer. Thus, the growing cancer patient pool burden in developed as well as developing countries is anticipated to accelerate the demand for epigenetic diagnostic kits and products. Consequently, it will help to bolster the market growth.
Report Scope and Market Segmentation
|
Report Metric
|
Details
|
|
Forecast Period
|
2022 to 2029
|
|
Base Year
|
2021
|
|
Historic Years
|
2020(Customizable to 2014 - 2019)
|
|
Quantitative Units
|
Revenue in USD Million, Volumes in Units, Pricing in USD
|
|
Segments Covered
|
Product (Reagents, Kits, Instruments & Consumables, Bioinformatics Tools & Enzymes), Technology (DNA Methylation, Histone Methylation, Chromatin Structures, Histone Acetylation, Large Non-Coding RNA & MicroRNA Modification), Type of Therapy (Histone Deacetylase (HDAC) Inhibitors, DNA Methyltransferase (DNMT) Inhibitors & Others), Application (Oncology, Cardiovascular Diseases, Metabolic Diseases, Immunology, Inflammatory Diseases, Infectious Diseases & Others), End User (Academic and Research Institutes, Pharmaceutical and Biotechnology Companies, Contract Research Organizations (CROs) and Others), Distribution Channel (Direct Tender & Retail Sales)
|
|
Countries Covered
|
U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.
|
|
Market Players Covered
|
Illumina, Inc. (US), Merck KGaA (Germany), QIAGEN (Germany), F. Hoffmann-La Roche Ltd (Switzerland), Eisai Co., Ltd. (Japan), Novartis AG (Switzerland), Abcam plc (U.K.), Diagenode s.a. (U.S.), Active Motif, Inc. (U.S.), Zymo Research Corporation. (U.S.), Thermo Fisher Scientific (U.S.), Cellcentric (Germany), Syndax (U.S.), New England Biolabs (U.S.), Epizyme, Inc. (U.S.), Domainex (U.K.), Agilent Technologies, Inc. (U.S.), PerkinElmer Inc. (U.S.), Bio-Rad Laboratories, Inc. (U.S.), AsisChem Inc. (U.S.), Enzo Life Sciences, Inc. (U.S.), EpiGentek Group Inc. (U.S.), BioVision Inc. (U.S.), Bio-Techne. (U.S.), Promega Corporation (US), GeneTex, Inc. (U.S.), Pacific Biosciences of California, Inc. (U.S.)
|
|
Data Points Covered in Report
|
In addition to the market insights such as market value, growth rate, market segments, geographical coverage, market players, and market scenario, the market report curated by the Data Bridge Market Research team also includes in-depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.
|
Segment Analysis:
Global epigenetics diagnostic market is categorized into six notable segments which are based on product, technology, type of therapy, application, end user, and distribution channel.
- On the basis of product, the global epigenetics diagnostic market is segmented into reagents, kits, instruments and consumables, bioinformatics tools, and enzymes. In 2021, reagents segment is expected to dominate the market growing with the highest CAGR of 15.6% in the forecast period of 2021 to 2028 as reagents are used in a variety of fields including research, diagnosis, bioscience, and education.
- On the basis of technology, the global epigenetics diagnostic market is segmented into DNA methylation, histone methylation, chromatin structures, histone acetylation, large non-coding RNA, and microRNA modification. In 2021, DNA methylation segment is expected to dominate the market growing with the highest CAGR of 17.2%
The DNA methylation segment is expected to dominate the market growing with the highest CAGR of 17.2%
In 2021, DNA methylation segment is expected to dominate the market growing with the highest CAGR of 17.2% in the forecast period of 2021 to 2028 as the DNA methylation technology is being used in a variety of epigenetics diagnosis.
- On the basis of type of therapy, the global epigenetics diagnostic market is segmented into histone deacetylase (HDAC) inhibitors, DNA methyltransferase (DNMT) inhibitors, and others. In 2021, histone deacetylase (HDAC) inhibitors segment is expected to dominate the market growing with the highest CAGR of 16.4% in the forecast period of 2021 to 2028 as it plays a major role in several biological processes, such as proliferation, cell cycle progression and differentiation. Histone deacetylase (HDAC) and their inhibitors can be used to post-translationally modify histones—the histone code that is read and recognized by other proteins to regulate gene expression.
- On the basis of application, the global epigenetics diagnostic market is segmented into oncology, cardiovascular diseases, metabolic diseases, immunology, inflammatory diseases, and others. In 2021, oncology segment is expected to dominate the market growing with the highest CAGR of 19.2% in the forecast period of 2021 to 2028 due to high prevalence of cancer across the globe.
- On the basis of end user, the global epigenetics diagnostic market is segmented into academic and research institutes, pharmaceutical and biotechnology companies, contract research organizations (CROs), and others. In 2021, academic and research institutes segment is expected to dominate the market and is growing with the highest CAGR of 17.6% in the forecast period of 2021 to 2028 as research institutes perform an essential role to accelerate research and development in various therapeutic areas related to epigenetics diagnosis.
- On the basis of distribution channel, the global epigenetics diagnostic market is segmented into direct tender and retail sales. In 2021, direct tender segment is expected to dominate the market growing with the highest CAGR of 15.8% in the forecast period of 2021 to 2028 due to escalation in marketing activities and improved customer services in developed as well as developing countries.
Major Players
Data Bridge Market Research recognizes the following companies as the major epigenetics diagnostic market players in epigenetics diagnostic market are Illumina, Inc. (US), Merck KGaA (Germany), QIAGEN (Germany), F. Hoffmann-La Roche Ltd (Switzerland), Eisai Co., Ltd. (Japan), Novartis AG (Switzerland), Abcam plc (U.K.), Diagenode s.a. (U.S.), Active Motif, Inc. (U.S.), Zymo Research Corporation. (U.S.), Thermo Fisher Scientific (U.S.), Cellcentric (Germany), Syndax (U.S.), New England Biolabs (U.S.), Epizyme, Inc. (U.S.), Domainex (U.K.), Agilent Technologies, Inc. (U.S.), PerkinElmer Inc. (U.S.), Bio-Rad Laboratories, Inc. (U.S.), AsisChem Inc. (U.S.), Enzo Life Sciences, Inc. (U.S.), EpiGentek Group Inc. (U.S.), BioVision Inc. (U.S.), Bio-Techne. (U.S.), Promega Corporation (US), GeneTex, Inc. (U.S.), Pacific Biosciences of California, Inc. (U.S.).
Market Development
- In September 2021, PerkinElmer Health Sciences, Inc., agreed with UPM Biomedicals to offer high throughput 3D cell screening solution. This collaboration help to expand offering for 3D cell culture models and further help researchers get to the critical insights they need faster to uncover successful drug candidates and thereby sustain footprints in the market.
- In August 2021, QIAGEN and OncXerna enter into a global master agreement to advance the development of the Xerna™ TME panel as a potential Next Generation Sequencing (NGS) companion diagnostic for OncXerna's Navicixizumab. The agreements broaden QIAGEN's NGS companion diagnostics capabilities in immuno- oncology clinical development programs, enhancing growth.
Regional Analysis
Geographically, the countries covered in the epigenetics diagnostic market report are U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.
As per Data Bridge Market Research analysis:
North America is the dominant region in epigenetics diagnostic market during the forecast period
North America dominated the epigenetics diagnostic market owing to the rise in number of cancer patients and large number of players' presence. North America will continue to dominate the epigenetics diagnostic market in terms of market share and market revenue and will continue to flourish its dominance during the forecast period due to the increasing healthcare expenditure.
Asia-Pacific is estimated to be the fastest growing region in epigenetics diagnostic market
Asia-Pacific is expected to grow during the forecast period due to the increased demand of epigenetics diagnosis along with growing geriatric population in this region. In addition, the growing presence of major market players and rising disposable income are expected to propel the market's growth rate in this region.
For more detailed information about the epigenetics diagnostic market report, click here – https://www.databridgemarketresearch.com/jp/reports/global-epigenetics diagnostic-market
